The growing demand for protein therapeutics due to the increase in the prevalence of chronic diseases is a major factor driving this market. Advances in cell-free systems and improved expression vectors, which enhance efficiency and productivity, also help to boost the protein synthesis market. The developments towards cell-free systems, high-throughput technologies, and a focus on personalized medicine also act as key factors for the growth of the protein synthesis market. The high production costs and complex techniques affect the growth of the market.
The market includes major players such as Amgen Inc., Pfizer Inc., Genentech, USA Inc., and Eli Lilly, which mainly focus on protein therapeutics. The companies focusing on protein synthesis research and development include GenScript ProBio, Aldevron, Creative Biogene, and Tierra Biosciences Inc.
The market includes major players such as Amgen Inc., Pfizer Inc., Genentech, USA Inc., and Eli Lilly, which mainly focus on protein therapeutics. The companies focusing on protein synthesis research and development include GenScript ProBio, Aldevron, Creative Biogene, and Tierra Biosciences Inc.
- The global market for commercial amino acids is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
- The global market for recombinant proteins is expected to grow from $141.8 billion in 2024 to $203.6 billion by 2029, at a CAGR of 7.5% from 2024 through 2029.
- The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 to $15.9 billion by 2028, at a CAGR of 9.4% from 2023 through 2028.
Research Review Scope
Protein synthesis is vital for all living organisms, enabling cells to produce the proteins they need to survive and function. It is a basic biological process that builds proteins in cells, which is essential for every cellular function. The key components of protein synthesis are Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), ribosomes, and amino acids.Table of Contents
Chapter 1 Foreword
- Research Review Scope
Chapter 2 Commercial Amino Acids (BIO007N)
- Market Outlook
- Scope of Report
- Market Summary
- Market Overview
- Commercial Interests
- Chemical Structure
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Challenges
- Market Opportunity
- Regulatory Structure
- Global Regulatory Framework
- Regulatory Requirements for Different Applications
- Quality Control and Manufacturing Standards
- Emerging Technologies and Developments
- Metabolic Engineering and Synthetic Biology
- High-throughput Screening and Fermentation Optimization
- Continuous-Flow Biocatalysis
- Advanced Chromatography Techniques
- Hydroxy Amino Acids
- Green Chemistry and Sustainable Production
- Key Market Trends
- Commercial Amino Acids: Global Markets
- Commercial Amino Acids Market, by Product Type
- Methionine
- Lysine
- Threonine
- Tryptophan
- Phenylalanine
- Glutamic Acid
- Cysteine
- Aspartic Acid
- Glycine
- Alanine
- Arginine
- Proline
- Leucine
- Valine
- Tyrosine
- Other Amino Acids
- Commercial Amino Acids Market, by Application
- Animal Feed Applications
- Food Flavoring Applications
- Specialty Uses Applications
- Commercial Amino Acids Market, by Region
- North America
- Europe
- Asia-Pacific
- LATAM
- Rest of the World
- Sustainability in Commercial Amino Acids: An ESG Perspective
- Introduction to ESG
- Sustainability in the Commercial Amino Acids Market
- Understanding the ESG Data
Chapter 3 Global Recombinant Proteins Market (BIO254A)
- Market Outlook
- Scope of Report
- Market Summary
- Market Overview
- Types of Expression Host Systems
- Mechanism of Action of Recombinant Proteins
- Common Steps Involved in Recombinant Protein Production
- Market Dynamics of Recombinant Proteins
- Drivers
- Restraints
- Opportunities
- Emerging Technologies and Developments in Recombinant Proteins
- Protein-Engineering Advances
- CRISPR Genome Editing
- Cell-Free Protein Synthesis
- Global Market for Recombinant Proteins, by Product Type
- Hormones
- Cytokines
- Enzymes
- Antibodies
- Antigens
- Others
- Global Market for Recombinant Proteins, by Host Cell Type
- Bacterial Host Cells
- Yeast and Fungi Cells
- Mammalian Cells
- Insect Cells
- Other Cells
- Global Market for Recombinant Proteins, by Application
- Therapeutics and Vaccines
- Biomedical Research
- Diagnostics
- Global Market for Recombinant Proteins, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Sustainability in the Recombinant Proteins Market
- Understanding the ESG Data
- ESG Performance Analysis
- Concluding Remarks
Chapter 4 Oligonucleotides: Global Markets (BIO220B)
- Market Outlook
- Scope of Report
- Market Insights
- Market Overview
- History of Oligonucleotide Synthesis
- Types of Oligonucleotides
- Alternative Forms of Oligonucleotide Synthesis
- Versatile Functions of Synthetic Oligonucleotides
- Regulatory Paths for Oligotherapeutics
- Animal Models and Studies
- Role of Regulatory Authorities
- Global Market Dynamics for Oligonucleotides
- Market Drivers
- Market Restraints
- Opportunities in the Market
- Emerging Applications in Various Fields
- Emerging Technologies and Developments in Oligonucleotides
- DNA Synthesizers
- Emerging Technologies
- Global Market for Oligonucleotide Synthesis, by Product Type
- Oligonucleotide Drugs
- Equipment and Reagents
- Synthesized Oligos
- Services
- Global Market for Oligonucleotide Synthesis, by Application
- Research
- Diagnostics and Therapeutics
- Global Market for Oligonucleotide Synthesis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- ESG Developments in the Oligonucleotide Market
- Introduction to ESG
- Assessing the Sustainability of the Oligonucleotide Manufacturing Process
- ESG Performance in Market
- Concluding Remarks
Chapter 5 PEGylated Proteins Market (BIO253A)
- Market Outlook
- Scope of Report
- Market Summary
- Market Overview
- Advantages of Protein PEGylation
- Limitations of PEGylated Therapeutics
- Market Dynamics for the PEGylated Proteins
- Market Drivers
- Market Restraints
- Market Opportunities
- Emerging Technologies and Developments
- Non-Covalent PEGylation
- PEGylation of Nanoparticles
- Antibody-Drug Conjugates (ADCs)
- Global PEGylated Proteins Market, by Protein Type
- Granulocyte-Colony Stimulating Factors (G-CSF)
- PEGylated Monoclonal Antibodies
- PEGylated Interferons
- PEGylated Recombinant Factors
- Other Protein Types
- Global PEGylated Proteins Market, by PEGylation Type
- Linear PEGylated Proteins
- Branched PEGylated Proteins
- Global PEGylated Proteins Market, by PEGylation Application
- Autoimmune Diseases
- Hematology
- Cancer
- Other Applications
- Global PEGylated Proteins Market, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Sustainability in PEGylated Proteins Market: ESG Perspective
- Introduction to ESG
- Sustainability in the PEGylated Proteins Industry
- Understanding the ESG Data
- ESG Performance Analysis
- Concluding Remarks
Chapter 6 Peptide Synthesis: Global Markets (BIO252A)
- Market Outlook
- Scope of Report
- Market Summary
- Peptide Therapeutics Market Overview
- Importance of Peptides
- Peptide Synthesis
- Trends in Peptide Therapeutics
- Market Dynamics
- Market Drivers
- Market Restraint
- Market Opportunities
- Emerging Technologies for Peptide Synthesis and Therapeutics Manufacturing
- Advances in SPPS in Aqueous Media
- Chemical Synthesis
- Peptide Drug Delivery
- Examples of New Developments, by Company
- Market Analysis, by Segment
- Global Market for Peptide Synthesis, by Peptide Type
- Synthetic Peptides
- Antimicrobial Peptides
- Hormonal Peptides
- Bioactive Peptides
- Collagen Peptides
- Other Products
- Global Market for Peptide Synthesis, by Application
- Peptide Therapeutics
- Cosmetics
- Nutraceuticals
- Other Applications
- Global Market for Peptide Synthesis, by Synthesis Type
- Solid-phase
- Solution-phase
- Hybrid-phase
- Global Market for Peptide Synthesis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Sustainability in the Peptide Synthesis Industry: ESG Perspective
- Importance of ESG among Peptide Therapeutics Manufacturers
- ESG Practices of Peptide Therapeutics Manufacturers
- BCC Research Viewpoint
Chapter 7 Appendix
- Research Methodology
- Analyst's Credentials
List of Tables
Table 1: Global Commercial Amino Acids Market, by Application, Through 2029
Table 2: Commercial Amino Acids, by Use
Table 3: Protein Amino Acids
Table 4: Applications of Selected Amino Acids
Table 5: Global Commercial Amino Acids Market, Through 2029
Table 6: Leading Global Producers of Amino Acids, by Product Type, 2023
Table 7: Global Commercial Amino Acids Market, by Product Type, Through 2029
Table 8: Methionine Content of Selected Foods
Table 9: Global Commercial Amino Acids Market, by Application, Through 2029
Table 10: Global Commercial Amino Acids Market, by Region, Through 2029
Table 11: North American Commercial Amino Acids Market, by Country, Through 2029
Table 12: European Commercial Amino Acids Market, by Country, Through 2029
Table 13: Asia-Pacific Commercial Amino Acids Market, by Country, Through 2029
Table 14: LATAM Commercial Amino Acids Market, by Country, Through 2029
Table 15: RoW Commercial Amino Acids Market, by Application, Through 2029
Table 16: ESG Rankings for Major Commercial Amino Acids Companies, 2024*
Table 17: Global Market for Recombinant Proteins, by Region, Through 2029
Table 18: Comparison of Different Protein Expression Host Systems
Table 19: R&D Expenditures of Key Biopharmaceutical Companies, 2023
Table 20: Global Market for Recombinant Proteins, by Product Type, Through 2029
Table 21: Global Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 22: Global Market for Recombinant Proteins, by Application, Through 2029
Table 23: Therapeutic Applications of Recombinant Proteins, by Product Type
Table 24: Global Market for Recombinant Proteins, by Region, Through 2029
Table 25: North American Market for Recombinant Proteins, by Country, Through 2029
Table 26: European Market for Recombinant Proteins, by Country, Through 2029
Table 27: Asia-Pacific Market for Recombinant Proteins, by Country, Through 2029
Table 28: ESG Rankings for Major Recombinant Protein Drug Companies, 2024*
Table 29: ESG: Environmental Overview
Table 30: ESG: Social Factors Overview
Table 31: ESG: Governance Overview
Table 32: Global Market for Oligonucleotides, by Region, Through 2028
Table 33: Comparison of Oligonucleotide and Polynucleotide
Table 34: List of Approved Oligonucleotide Therapeutics, 2023
Table 35: Global Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 36: Revenue Generated, by Few Oligonucleotide Drugs, 2022
Table 37: Global Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 38: Global Market for Oligonucleotide Synthesis, by Region, Through 2028
Table 39: North American Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 40: European Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 41: Asia-Pacific Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 42: Assessment of the Oligonucleotide Manufacturing Process Against the 12 Principles of Green Chemistry
Table 43: Key Focus Areas in ESG Metrics
Table 44: ESG Rankings for Oligonucleotide Companies, 2023*
Table 45: Global Market for PEGylated Proteins, by Region, Through 2028
Table 46: PEGylated Drugs in Clinical Trials for Cancer
Table 47: Discontinued PEGylated Drugs in Clinical Trials
Table 48: Side Effects Observed with Approved Products
Table 49: Global Market for PEGylated Proteins, by Protein Type, Through 2028
Table 50: Marketed PEGylated G-CSF Drugs
Table 51: Global Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 52: Global Market for PEGylated Proteins, by Application, Through 2028
Table 53: Global Market for PEGylated Proteins, by Region, Through 2028
Table 54: North American Market for PEGylated Proteins, by Country, Through 2028
Table 55: North American Market for PEGylated Proteins, by Protein Type, Through 2028
Table 56: North American Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 57: North American Market for PEGylated Proteins, by Application, Through 2028
Table 58: European Market for PEGylated Proteins, by Country, Through 2028
Table 59: European Market for PEGylated Proteins, by Protein Type, Through 2028
Table 60: European Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 61: European Market for PEGylated Proteins, by Application, Through 2028
Table 62: Asia-Pacific Market for PEGylated Proteins, by Country, Through 2028
Table 63: Asia-Pacific Market for PEGylated Proteins, by Protein Type, Through 2028
Table 64: Asia-Pacific Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 65: Asia-Pacific Market for PEGylated Proteins, by Application, Through 2028
Table 66: RoW Market for PEGylated Proteins, by Protein Type, Through 2028
Table 67: RoW Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 68: RoW Market for PEGylated Proteins, by Application, Through 2028
Table 69: ESG Risk Rankings for Major PEGylated Protein Drug Companies, 2024*
Table 70: ESG: Environmental Overview
Table 71: ESG: Social Overview
Table 72: ESG: Governance Overview
Table 73: Global Market for Peptide Synthesis, by Peptide Type, Through 2028
Table 74: Pros and Cons of Liquid Phase and Solid Phase Synthesis
Table 75: Global Cancer Incidence, 2020
Table 76: Emerging Trends in Peptide Synthesis Technologies
Table 77: Global Market for Peptide Synthesis, by Peptide Type, Through 2028
Table 78: Global Market for Peptide Synthesis, by Application, Through 2028
Table 79: Peptide-based Drugs Approved by FDA in 2021
Table 80: Best-Selling Peptide Therapeutics, 1982-2021
Table 81: Global Market for Peptide Synthesis, by Synthesis Type, Through 2028
Table 82: Global Market for Peptide Synthesis, by Region, Through 2028
Table 83: North American Market for Peptide Synthesis, by Country, Through 2028
Table 84: European Market for Peptide Synthesis, by Country, Through 2028
Table 85: Asia-Pacific Market for Peptide Synthesis, by Country, Through 2028
Table 86: RoW Market for Peptide Synthesis, by Country, Through 2028
Table 87: Role of ESG in Environmental Performance
Table 88: Role of ESG in Social Performance
Table 89: Role of ESG in Governance Performance
Table 90: ESG Rankings for Major Peptide Therapeutics Companies, 2023*
Table 2: Commercial Amino Acids, by Use
Table 3: Protein Amino Acids
Table 4: Applications of Selected Amino Acids
Table 5: Global Commercial Amino Acids Market, Through 2029
Table 6: Leading Global Producers of Amino Acids, by Product Type, 2023
Table 7: Global Commercial Amino Acids Market, by Product Type, Through 2029
Table 8: Methionine Content of Selected Foods
Table 9: Global Commercial Amino Acids Market, by Application, Through 2029
Table 10: Global Commercial Amino Acids Market, by Region, Through 2029
Table 11: North American Commercial Amino Acids Market, by Country, Through 2029
Table 12: European Commercial Amino Acids Market, by Country, Through 2029
Table 13: Asia-Pacific Commercial Amino Acids Market, by Country, Through 2029
Table 14: LATAM Commercial Amino Acids Market, by Country, Through 2029
Table 15: RoW Commercial Amino Acids Market, by Application, Through 2029
Table 16: ESG Rankings for Major Commercial Amino Acids Companies, 2024*
Table 17: Global Market for Recombinant Proteins, by Region, Through 2029
Table 18: Comparison of Different Protein Expression Host Systems
Table 19: R&D Expenditures of Key Biopharmaceutical Companies, 2023
Table 20: Global Market for Recombinant Proteins, by Product Type, Through 2029
Table 21: Global Market for Recombinant Proteins, by Host Cell Type, Through 2029
Table 22: Global Market for Recombinant Proteins, by Application, Through 2029
Table 23: Therapeutic Applications of Recombinant Proteins, by Product Type
Table 24: Global Market for Recombinant Proteins, by Region, Through 2029
Table 25: North American Market for Recombinant Proteins, by Country, Through 2029
Table 26: European Market for Recombinant Proteins, by Country, Through 2029
Table 27: Asia-Pacific Market for Recombinant Proteins, by Country, Through 2029
Table 28: ESG Rankings for Major Recombinant Protein Drug Companies, 2024*
Table 29: ESG: Environmental Overview
Table 30: ESG: Social Factors Overview
Table 31: ESG: Governance Overview
Table 32: Global Market for Oligonucleotides, by Region, Through 2028
Table 33: Comparison of Oligonucleotide and Polynucleotide
Table 34: List of Approved Oligonucleotide Therapeutics, 2023
Table 35: Global Market for Oligonucleotide Synthesis, by Product Type, Through 2028
Table 36: Revenue Generated, by Few Oligonucleotide Drugs, 2022
Table 37: Global Market for Oligonucleotide Synthesis, by Application, Through 2028
Table 38: Global Market for Oligonucleotide Synthesis, by Region, Through 2028
Table 39: North American Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 40: European Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 41: Asia-Pacific Market for Oligonucleotide Synthesis, by Country, Through 2028
Table 42: Assessment of the Oligonucleotide Manufacturing Process Against the 12 Principles of Green Chemistry
Table 43: Key Focus Areas in ESG Metrics
Table 44: ESG Rankings for Oligonucleotide Companies, 2023*
Table 45: Global Market for PEGylated Proteins, by Region, Through 2028
Table 46: PEGylated Drugs in Clinical Trials for Cancer
Table 47: Discontinued PEGylated Drugs in Clinical Trials
Table 48: Side Effects Observed with Approved Products
Table 49: Global Market for PEGylated Proteins, by Protein Type, Through 2028
Table 50: Marketed PEGylated G-CSF Drugs
Table 51: Global Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 52: Global Market for PEGylated Proteins, by Application, Through 2028
Table 53: Global Market for PEGylated Proteins, by Region, Through 2028
Table 54: North American Market for PEGylated Proteins, by Country, Through 2028
Table 55: North American Market for PEGylated Proteins, by Protein Type, Through 2028
Table 56: North American Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 57: North American Market for PEGylated Proteins, by Application, Through 2028
Table 58: European Market for PEGylated Proteins, by Country, Through 2028
Table 59: European Market for PEGylated Proteins, by Protein Type, Through 2028
Table 60: European Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 61: European Market for PEGylated Proteins, by Application, Through 2028
Table 62: Asia-Pacific Market for PEGylated Proteins, by Country, Through 2028
Table 63: Asia-Pacific Market for PEGylated Proteins, by Protein Type, Through 2028
Table 64: Asia-Pacific Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 65: Asia-Pacific Market for PEGylated Proteins, by Application, Through 2028
Table 66: RoW Market for PEGylated Proteins, by Protein Type, Through 2028
Table 67: RoW Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 68: RoW Market for PEGylated Proteins, by Application, Through 2028
Table 69: ESG Risk Rankings for Major PEGylated Protein Drug Companies, 2024*
Table 70: ESG: Environmental Overview
Table 71: ESG: Social Overview
Table 72: ESG: Governance Overview
Table 73: Global Market for Peptide Synthesis, by Peptide Type, Through 2028
Table 74: Pros and Cons of Liquid Phase and Solid Phase Synthesis
Table 75: Global Cancer Incidence, 2020
Table 76: Emerging Trends in Peptide Synthesis Technologies
Table 77: Global Market for Peptide Synthesis, by Peptide Type, Through 2028
Table 78: Global Market for Peptide Synthesis, by Application, Through 2028
Table 79: Peptide-based Drugs Approved by FDA in 2021
Table 80: Best-Selling Peptide Therapeutics, 1982-2021
Table 81: Global Market for Peptide Synthesis, by Synthesis Type, Through 2028
Table 82: Global Market for Peptide Synthesis, by Region, Through 2028
Table 83: North American Market for Peptide Synthesis, by Country, Through 2028
Table 84: European Market for Peptide Synthesis, by Country, Through 2028
Table 85: Asia-Pacific Market for Peptide Synthesis, by Country, Through 2028
Table 86: RoW Market for Peptide Synthesis, by Country, Through 2028
Table 87: Role of ESG in Environmental Performance
Table 88: Role of ESG in Social Performance
Table 89: Role of ESG in Governance Performance
Table 90: ESG Rankings for Major Peptide Therapeutics Companies, 2023*
List of Figures
Figure 1: Snapshot of the Market Dynamics for Commercial Amino Acids
Figure 2: Global Commercial Amino Acids Market Share, by Product Type, 2023
Figure 3: Global Commercial Amino Acids Market Share, by Application, 2023
Figure 4: Global Commercial Amino Acids Market Share, by Region, 2023
Figure 5: North American Commercial Amino Acids Market Share, by Country, 2023
Figure 6: European Commercial Amino Acids Market Share, by Country, 2023
Figure 7: Asia-Pacific Commercial Amino Acids Market Share, by Country, 2023
Figure 8: LATAM Commercial Amino Acids Market Share, by Country, 2023
Figure 9: Global Market Shares of Recombinant Proteins, by Region, 2023
Figure 10: Basic Steps Involved in Recombinant Protein Production
Figure 11: Snapshot of the Market Dynamics of Recombinant Proteins
Figure 12: Global Biopharmaceutical R&D Expenditures, 2020-2026
Figure 13: Applications of Recombinant Antibodies
Figure 14: Advantages and Disadvantages of Continuous Manufacturing
Figure 15: Global Market Shares of Recombinant Proteins, by Product Type, 2023
Figure 16: Advantages of Recombinant Antibodies
Figure 17: Global Market Shares of Recombinant Proteins, by Host Cell Type, 2023
Figure 18: Global Market Shares of Recombinant Proteins, by Application, 2023
Figure 19: North American Market Shares of Recombinant Proteins, by Country, 2023
Figure 20: European Market Shares of Recombinant Proteins, by Country, 2023
Figure 21: Asia-Pacific Market Shares of Recombinant Proteins, by Country, 2023
Figure 22: Key ESG Metrics of Recombinant Protein Companies
Figure 23: Global Market Shares of Oligonucleotides, by Region, 2022
Figure 24: Classification of Synthetic Oligonucleotides
Figure 25: Dynamics of the Global Market for Oligonucleotides
Figure 26: Global Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 27: Global Market Shares of Oligonucleotide Synthesis, by Application, 2022
Figure 28: North American Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 29: European Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 30: Asia-Pacific Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 31: How a Strong ESG Proposition Benefits Businesses
Figure 32: ESG Adoption Level across Industries, 2021 and 2022
Figure 33: Advantages of Protein PEGylation
Figure 34: Timeline of PEGylated Protein Therapeutics
Figure 35: Disadvantages of PEGylated Protein Therapeutics
Figure 36: Market Dynamics of Global PEGylated Proteins
Figure 37: Emerging Technologies in the PEGylated Proteins Market
Figure 38: Global Market Shares of PEGylated Proteins, by Protein Type, 2022
Figure 39: Global Market Shares of PEGylated Proteins, by PEGylation Type, 2022
Figure 40: Global Market Shares of PEGylated Proteins, by Application, 2022
Figure 41: Global Market Shares of PEGylated Proteins, by Region, 2022
Figure 42: North American Market Shares of PEGylated Proteins, by Country, 2022
Figure 43: European Market Shares of PEGylated Proteins, by Country, 2022
Figure 44: Asia-Pacific Market Shares of PEGylated Proteins, by Country, 2022
Figure 45: Snapshot of ESG Pillars
Figure 46: Advantages of ESG for Companies
Figure 47: Global Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 48: Trends in Peptide Therapeutics Manufacturing
Figure 49: Snapshot of the Market Dynamics for Peptide Synthesis
Figure 50: India’s Biotechnology Sectoral Thrust
Figure 51: Global Projected Incidence of Diabetes, Patients Aged 20-79 Years, 2010 and 2030
Figure 52: Global Infectious Disease Outbreaks, 2020 to 2022
Figure 53: Global Infectious Disease Outbreak, 2022
Figure 54: Snapshot: Key Trends in Peptide Drugs and Therapeutics Technologies
Figure 55: Global Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 56: Global Market Shares of Peptide Synthesis, by Application, 2022
Figure 57: Global Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 58: Global Market Shares of Peptide Synthesis, by Region, 2022
Figure 59: North American Market Shares of Peptide Synthesis, by Application, 2022
Figure 60: North American Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 61: North American Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 62: North American Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 63: North American Market Shares of Peptide Synthesis, by Country, 2022
Figure 64: European Market Shares of Peptide Synthesis, by Application, 2022
Figure 65: European Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 66: European Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 67: European Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 68: European Market Shares of Peptide Synthesis, by Country, 2022
Figure 69: Asia-Pacific Market Shares of Peptide Synthesis, by Application, 2022
Figure 70: Asia-Pacific Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 71: Asia-Pacific Market Shares of Peptide Synthesis, by Peptide Types, 2022
Figure 72: Asia-Pacific Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 73: Asia-Pacific Market Shares of Peptide Synthesis, by Country, 2022
Figure 74: RoW Market Shares of Peptide Synthesis, by Application, 2022
Figure 75: RoW Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 76: RoW Market Shares of Peptide Synthesis, by Peptide Types, 2022
Figure 77: RoW Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 78: RoW Market Shares of Peptide Synthesis, by Country/Region, 2022
Figure 79: Snapshot: Key ESG Trends in Peptide Therapeutics Industry
Figure 2: Global Commercial Amino Acids Market Share, by Product Type, 2023
Figure 3: Global Commercial Amino Acids Market Share, by Application, 2023
Figure 4: Global Commercial Amino Acids Market Share, by Region, 2023
Figure 5: North American Commercial Amino Acids Market Share, by Country, 2023
Figure 6: European Commercial Amino Acids Market Share, by Country, 2023
Figure 7: Asia-Pacific Commercial Amino Acids Market Share, by Country, 2023
Figure 8: LATAM Commercial Amino Acids Market Share, by Country, 2023
Figure 9: Global Market Shares of Recombinant Proteins, by Region, 2023
Figure 10: Basic Steps Involved in Recombinant Protein Production
Figure 11: Snapshot of the Market Dynamics of Recombinant Proteins
Figure 12: Global Biopharmaceutical R&D Expenditures, 2020-2026
Figure 13: Applications of Recombinant Antibodies
Figure 14: Advantages and Disadvantages of Continuous Manufacturing
Figure 15: Global Market Shares of Recombinant Proteins, by Product Type, 2023
Figure 16: Advantages of Recombinant Antibodies
Figure 17: Global Market Shares of Recombinant Proteins, by Host Cell Type, 2023
Figure 18: Global Market Shares of Recombinant Proteins, by Application, 2023
Figure 19: North American Market Shares of Recombinant Proteins, by Country, 2023
Figure 20: European Market Shares of Recombinant Proteins, by Country, 2023
Figure 21: Asia-Pacific Market Shares of Recombinant Proteins, by Country, 2023
Figure 22: Key ESG Metrics of Recombinant Protein Companies
Figure 23: Global Market Shares of Oligonucleotides, by Region, 2022
Figure 24: Classification of Synthetic Oligonucleotides
Figure 25: Dynamics of the Global Market for Oligonucleotides
Figure 26: Global Market Shares of Oligonucleotide Synthesis, by Product Type, 2022
Figure 27: Global Market Shares of Oligonucleotide Synthesis, by Application, 2022
Figure 28: North American Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 29: European Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 30: Asia-Pacific Market Shares of Oligonucleotide Synthesis, by Country, 2022
Figure 31: How a Strong ESG Proposition Benefits Businesses
Figure 32: ESG Adoption Level across Industries, 2021 and 2022
Figure 33: Advantages of Protein PEGylation
Figure 34: Timeline of PEGylated Protein Therapeutics
Figure 35: Disadvantages of PEGylated Protein Therapeutics
Figure 36: Market Dynamics of Global PEGylated Proteins
Figure 37: Emerging Technologies in the PEGylated Proteins Market
Figure 38: Global Market Shares of PEGylated Proteins, by Protein Type, 2022
Figure 39: Global Market Shares of PEGylated Proteins, by PEGylation Type, 2022
Figure 40: Global Market Shares of PEGylated Proteins, by Application, 2022
Figure 41: Global Market Shares of PEGylated Proteins, by Region, 2022
Figure 42: North American Market Shares of PEGylated Proteins, by Country, 2022
Figure 43: European Market Shares of PEGylated Proteins, by Country, 2022
Figure 44: Asia-Pacific Market Shares of PEGylated Proteins, by Country, 2022
Figure 45: Snapshot of ESG Pillars
Figure 46: Advantages of ESG for Companies
Figure 47: Global Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 48: Trends in Peptide Therapeutics Manufacturing
Figure 49: Snapshot of the Market Dynamics for Peptide Synthesis
Figure 50: India’s Biotechnology Sectoral Thrust
Figure 51: Global Projected Incidence of Diabetes, Patients Aged 20-79 Years, 2010 and 2030
Figure 52: Global Infectious Disease Outbreaks, 2020 to 2022
Figure 53: Global Infectious Disease Outbreak, 2022
Figure 54: Snapshot: Key Trends in Peptide Drugs and Therapeutics Technologies
Figure 55: Global Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 56: Global Market Shares of Peptide Synthesis, by Application, 2022
Figure 57: Global Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 58: Global Market Shares of Peptide Synthesis, by Region, 2022
Figure 59: North American Market Shares of Peptide Synthesis, by Application, 2022
Figure 60: North American Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 61: North American Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 62: North American Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 63: North American Market Shares of Peptide Synthesis, by Country, 2022
Figure 64: European Market Shares of Peptide Synthesis, by Application, 2022
Figure 65: European Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 66: European Market Shares of Peptide Synthesis, by Peptide Type, 2022
Figure 67: European Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 68: European Market Shares of Peptide Synthesis, by Country, 2022
Figure 69: Asia-Pacific Market Shares of Peptide Synthesis, by Application, 2022
Figure 70: Asia-Pacific Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 71: Asia-Pacific Market Shares of Peptide Synthesis, by Peptide Types, 2022
Figure 72: Asia-Pacific Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 73: Asia-Pacific Market Shares of Peptide Synthesis, by Country, 2022
Figure 74: RoW Market Shares of Peptide Synthesis, by Application, 2022
Figure 75: RoW Market Shares of Peptide Therapeutics in Peptide Synthesis, by Application, 2022
Figure 76: RoW Market Shares of Peptide Synthesis, by Peptide Types, 2022
Figure 77: RoW Market Shares of Peptide Synthesis, by Synthesis Type, 2022
Figure 78: RoW Market Shares of Peptide Synthesis, by Country/Region, 2022
Figure 79: Snapshot: Key ESG Trends in Peptide Therapeutics Industry
